NCT06655155 (eSScape) is a Phase 2 clinical trial of Efgartigimod PH20 SC in Systemic Sclerosis (SSc), sponsored by argenx.

Who is sponsoring NCT06655155?

NCT06655155 is sponsored by argenx.

What drugs are being tested in NCT06655155?

Interventions in NCT06655155: Efgartigimod PH20 SC, Placebo PH20 SC.

What condition does NCT06655155 study?

NCT06655155 studies Systemic Sclerosis (SSc).

Is NCT06655155 still recruiting?

NCT06655155 is currently recruiting now. Last updated 11 March 2026.

Last reviewed 2026-03-11 · How we verify

NCT06655155: eSScape

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

Recruiting now Phase 2 Last updated 11 March 2026

What this trial tests

Phase 2 trial testing Efgartigimod PH20 SC in Systemic Sclerosis (SSc) in 81 participants. Currently enrolling.

Timeline

11 November 2024

Primary endpoint
17 August 2026

14 June 2027

Quick facts

Lead sponsor	argenx
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	81
Start date	11 November 2024
Primary completion	17 August 2026
Estimated completion	14 June 2027
Sites	69 locations across Italy, Poland, Croatia, Denmark, Netherlands, Belgium, Lithuania, Bulgaria

Drugs / interventions tested

Efgartigimod PH20 SC — full drug profile →
Placebo PH20 SC

Conditions studied

Systemic Sclerosis (SSc) — all drugs for Systemic Sclerosis (SSc) →

Sponsor

argenx — full company profile →

Who can join

18 and older, any sex, with Systemic Sclerosis (SSc). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of this study is to evaluate the effect and safety of efgartigimod PH20 SC compared to placebo in adults with systemic sclerosis. The study consists of a screening period, a treatment period of up to 48 weeks and a safety follow-up period. After the screening period, eligible participants will be randomized in a 2:1 ratio to receive either efgartigimod PH20 SC or placebo. The total study duration can be up to approximately 15 months. More information can be found on: https://clinicaltrials.argenx.com/esscape

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

From permeation enhancer to therapeutic enabler: Advances, applications, and translational perspectives in hyaluronidase-based drug delivery.
Seo Y, Sung J, Lee JY. · · 2026 · PMID 41960159 · DOI 10.1016/j.mtbio.2026.103052

Verify or expand the search:

Other trials of Efgartigimod PH20 SC

Trials testing the same drug.

NCT06637072 — A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC · Phase 4 · completed
NCT06392386 — A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis · Phase 2, PHASE3 · recruiting
NCT06307626 — A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease. · Phase 3 · terminated
NCT06307613 — A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease · Phase 3 · terminated
NCT04687072 — A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thro · Phase 3 · completed

Other recruiting trials for Systemic Sclerosis (SSc)

Currently open trials in the same condition.

NCT07526350 — MTS109 in Patients With Refractory Autoimmune Diseases · EARLY_PHASE1 · recruiting
NCT07087912 — Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases · Phase 4 · recruiting
NCT07413341 — A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases · Phase 1 · recruiting
NCT07360808 — Safety and Efficacy of Adipose-Derived Regenerative Cells (ADRCs) for Improving Hand Dysfunction in Systemic Sclerosis · NA · recruiting
NCT07292961 — Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed Wi · NA · recruiting

Other argenx trials

Trials by the same sponsor.

NCT07377396 — A Study to Assess the Safety of ARGX-124 in Healthy Volunteers · Phase 1 · recruiting
NCT07287982 — A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration · Phase 2 · recruiting
NCT07284420 — ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With · Phase 2 · recruiting
NCT07294170 — ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Particip · recruiting
NCT07091630 — A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06655155 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by argenx
Last refreshed: 11 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06655155.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing